Nationwide cohort study demonstrates that short-acting beta2-agonist overuse increases exacerbation and mortality risks in asthma patients, highlighting the critical need for usage monitoring.
One-third of asthma patients in Sweden collected three or more SABA canisters annually. SABA overuse was associated with increased risks of exacerbation and mortality. These findings emphasise that monitoring of SABA usage should be key in improving asthma management.
No takes yet. Share an insight, caveat, or question.
Nwaru et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: